This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Lee B. Reichman, MD, MPH
New Jersey Medical School University of Medicine and Dentistry of New Jersey Newark

JAMA. 1989;261(22):3246.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

The recent article¹ on the use of BCG vaccine in the control of tuberculosis is an important, authoritative statement that places in perspective the weaknesses in BCG protection and outlines its proper role in the prevention and control of tuberculosis, at least in the developed world.

Especially welcome are the discontinuation of recommendations for giving BCG to health care workers and the (implied) recommendation that all high-risk reactors by American Thoracic Society/Centers for Disease Control criteria,² especially health care workers, receive preventive therapy whether or not they have a history of BCG vaccination!

I am, however, concerned about the role of BCG in individuals at high risk of human immunodeficiency virus (HIV) infection, especially in areas with a high prevalence of HIV and frequent use of BCG. While stating that BCG should not be given to persons whose immunologic responses are impaired and while admitting . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?